A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
Berkshire Hathaway Inc. Cl A 2.50% $998.73B Berkshire Hathaway Inc. Cl B 2.48% $998.73B ...
Historical Prices for U.S. Global Technology and Aerospace & Defense ETF Loading.. Sustainability Rating Investment Policy Indices Commodities Currencies Stocks ...